Trials / Completed
CompletedNCT06930989
Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022
Twin Threat of OSA and Hypertension on Mortality/CV-risk and Protective Effect by Positive Airway Pressure Treatment.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 148,467 (actual)
- Sponsor
- Vastra Gotaland Region · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failure and stroke. OSA is also an independent promoter of hypertension development and poorly controlled hypertension is overrepresented in OSA. Finally, HT and OSA share many risk factors including obesity, and several lifestyle factors. Altogether, these links contribute to a high prevalence of patients with both disorders. The investigators suspect participants with HT and OSA are at even higher CV risk and may get their first CV event earlier in life. Comparison between HT and OSA participants vs HT alone, OSA alone or healthy controls has not previously been investigated in large studies. Thus, the investigators aim to investigate long-term risk of major cardiovascular events (MACE) or death comparing these groups in registry data between 2010-2022 in Sweden. The investigators will also investigate the protecting effect of positive airway pressure (PAP) on the OSA related CV risk increase and how many hours/night of PAP use is needed to get any protective effects.
Detailed description
Please see attached analysis plan
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Positive airway pressure (PAP) | Intervention as part of routine clinical care. Data from national registries. |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2025-04-08
- Completion
- 2025-04-30
- First posted
- 2025-04-16
- Last updated
- 2025-05-23
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT06930989. Inclusion in this directory is not an endorsement.